Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma.

However, there was no statistically significant difference in terms of mPFS between the combination treatment and lenvatinib alone (HR: 0.66; 95% CI 0.39–1.10; P =0.12), despite a favorable trend. 35 Notably, the benefit in terms of PFS was confirmed by a blinded independent radiologic assessment. 37 Overall response rate (ORR) was 43% for patients receiving the combination therapy, compared to 6% for patients treated with everolimus alone (rate ratio 7.2; 95% CI 2.3–22.5; P <0.0001); ORR was 27% for the single-agent lenvatinib arm, but data compared to those of the combination arm were not statistically significant (rate ratio 1.6; 95% CI 0.9–2.8; P =0.10).

also in 1,335 other papers